Clinical trials: Staphylococcus Aureus Bloodstream Infection, active
Staphylococcus Aureus
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis…
- Trial name
- PEAK (NCT06749457)
- Testing
- AZD7760
- Where
- 40 sites in United States
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Staphylococcus Aureus, Bacteremia
Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score < 3
Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide.
- Conditions
- Staphylococcus Aureus, Bacteremia, Infective Endocarditis
- Trial name
- VIRSTA-VAL (NCT06457386)
- Testing
- systematic echocardiography, no echocardiography arm
- Where
- France
- Volunteers
- 700 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Linezolid Plus Standard of Care
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- Trial name
- LIPS (NCT06958835)
- Testing
- Linezolid 600 mg
- Where
- 12 sites in Switzerland
- Volunteers
- 606 people
- Sponsor
- University Hospital, Basel, Switzerland
Immune Response To Sepsis, Staphylococcus Aureus Infection
Immune Resolution After Staphylococcus Aureus Bacteremia
The purpose of this study is to determine how monocyte HLA-DR and other markers of immune function change with time in patients with and without prior immune dysfunction who survive sepsis from Staphylococcus aureus bacteremia.
- Trial name
- NCT01879761
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- University of Chicago
Bacteriemia, Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Background Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a common and serious infection, associated with significant morbidity and high mortality rates.
- Trial name
- TriPasCef (NCT07186894)
- Testing
- Antistaphylococcal penicillins, Cefazolin
- Volunteers
- 5,000 people
- Sponsor
- Central Hospital, Nancy, France
Catheter Bacteremia, Staphylococcus Aureus Infection
Dalbavancin Versus Standard Antibiotic Therapy for Catheter-related Bloodstream Infections Due to Staphylococcus Aureus
The primary objective of the study is to demonstrate, among patients with non-complicated CR-BSIs due to S. aureus, that a single-dose of intravenous (IV) dalbavancin 1500 mg is non-inferior to standard documented antibiotic…
- Trial name
- DALICATH (NCT05117398)
- Testing
- Dalbavancin administration, Standard antibiotic therapy
- Where
- 2 sites in France
- Volunteers
- 406 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
- Trial name
- CERT (NCT04886284)
- Testing
- Ertapenem
- Where
- 7 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking aspirin for secondary prevention of cardiovascular events.
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- Clopido-SNAP 2 (NCT06650488)
- Testing
- Clopidogrel, Aspirin
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Sepsis, Sepsis Mrsa
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
The goal of this quasi-experimental interventional study is to determine the effectiveness of a multifaceted stewardship intervention in reducing overall vancomycin use in five tertiary care Pediatric Intensive Care Units (PICU).
- Conditions
- Sepsis, Sepsis Mrsa, Sepsis Bacteremia, Antimicrobial - Induced Nephropathy
- Trial name
- REVAMP (NCT05975671)
- Testing
- Multifaceted de-implementation strategy to reduce vancomycin overuse
- Where
- 4 sites in United States
- Volunteers
- 52,500 people
- Sponsor
- Children's Hospital of Philadelphia
Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia
Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia
The goal of this study is to investigate if benzylpenicillin is a better treatment option than cloxacillin in patients with penicillin-susceptible Staphylococcus aureus bacteraemia.
- Conditions
- Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia, Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia), Staphylococcus (S.) Aureus Infection
- Trial name
- COMeBAC (NCT06726395)
- Testing
- Penicillin G_1200mg, cloxacillin
- Where
- Sweden
- Volunteers
- 420 people
- Sponsor
- Region Skane
Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
- Conditions
- Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection
- Trial name
- DAPTO-SNAP (NCT06637332)
- Testing
- Daptomycin for Injection, Vancomycin (IV)
- Where
- 20 sites in Australia, Canada and 1 more
- Volunteers
- 300 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Staphylococcus Aureus Bloodstream Infection
A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults
The purpose of this study is to evaluate the safety and PK of AZD7760 when given as an intravenous (IV) infusion to healthy Japanese adult participants.
- Trial name
- NCT07612813
- Testing
- AZD7760
- Where
- Japan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- AstraZeneca